Aptevo Therapeutics Inc. (APVO) — Financial statements
Income statement, balance sheet, and cash flow for Aptevo Therapeutics Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00↓100.0% | 3↓74.7% | 12 | |
| Cost of Revenue | 0.24↓31.8% | 0.35 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | -0.24↑31.8% | -0.35 | 0.00↓100.0% | 3↓74.7% | 12 | |
| Operating Expenses | ||||||
| R&D Expenses | 15↑1.1% | 14↓16.0% | 17↓4.3% | 18↓5.9% | 19 | |
| General & Administrative Expenses | 12↑15.1% | 10↓13.1% | 12↓15.2% | 14↓5.6% | 15 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 12↑15.1% | 10↓13.1% | 12↓15.2% | 14↓5.6% | 15 | |
| Other Expenses | -0.24↑31.8% | -0.35 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 26↑7.5% | 24↓16.0% | 29↓9.1% | 32↓5.7% | 34 | |
| Total Costs & Expenses | 26↑7.0% | 25↓14.8% | 29↓9.1% | 32↓5.7% | 34 | |
| Operating Results | ||||||
| Operating Income | -26↓7.0% | -25↑14.8% | -29↓0.8% | -29↓33.8% | -21 | |
| Depreciation & Amortization | 0.24↓31.8% | 0.35↓37.9% | 0.57↓37.1% | 0.90↓21.2% | 1 | |
| EBITDA | -26↓9.6% | -24↑16.0% | -28↓2.1% | -28↓36.9% | -20 | |
| EBIT | -26↓9.0% | -24↑16.4% | -29↓0.8% | -29↓33.8% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00↑100.0% | -0.47 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 0.35↓26.9% | 0.47↓95.4% | 10↓71.3% | 36↑545.2% | -8 | |
| Income Before Tax | -26↓7.6% | -24↓29.4% | -19↓365.9% | 7↑123.9% | -29 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -26↓7.6% | -24↓29.4% | -19↓365.9% | 7↑123.9% | -29 | |
| Net Income from Discontinued Operations | 0.00 | 0.00↓100.0% | 1↑22.3% | 1↑6.5% | 0.95 | |
| Net Income | -26↓7.6% | -24↓38.6% | -17↓316.9% | 8↑128.2% | -28 | |
| Bottom-Line Net Income | -28↓14.1% | -24↓38.6% | -17↓316.9% | 8↑128.2% | -28 | |
| EPS (Basic) | -87.27↑99.7% | -31,458.00↑96.2% | -834,044.00↓190.4% | 922,390.00↑125.9% | -3,557,646.00 | |
| EPS (Diluted) | -87.27↑99.7% | -31,458.00↑96.2% | -834,044.00↓190.5% | 921,915.00↑125.9% | -3,557,646.00 | |
| Weighted Average Shares | 0.00↑311.3% | 0.00↑3735.0% | 0.00↑150.0% | 0.00↑14.3% | 0.00 | |
| Weighted Average Diluted Shares | 0.00↑311.3% | 0.00↑3735.0% | 0.00↑150.0% | 0.00↑14.3% | 0.00 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.